Article

Artificial tear formulations equally effective, study finds

The scores for the three main outcomes measured were totaled to arrive at the OSDI score.

The two formulations differ in that Refresh Tears is a carboxymethylcellulose-based artificial tear with purite preservatives. Carboxymethylcellulose, according to Dr. Lau, is an ionic polymer with cytoprotective properties, and purite is a stabilized oxychloro complex that dissociates into water, sodium, and chloride ions upon contact with the ocular surface, minimizing the toxic effects of a preservative. Tears Naturale Free is preservative-free artificial tears containing hydroxypropyl methylcellulose; this formulation has no toxic effect on the corneal epithelial cells, he said.

Dr. Yip, consultant, Department of Ophthalmology, Alexandra Hospital and Tan Tock Seng Hospital, Singapore, conducted a randomized, prospective clinical trial with Dr. Lau and his colleagues to compare the subjective effect of the two dry eye formulations on dry eye symptoms.

To be included in the study patients had to be 18 years or older, have symptoms of dry eye, a Schirmer's test result less than 10 mm in both eyes, and be using artificial tears for symptom relief, Dr. Lau explained.

Patients were excluded if they had ocular inflammation or allergies, used punctal plugs, had a disease of the lacrimal drainage system, wore contact lenses, or used topical steroid or immunosuppressant drugs.

Thirty-three patients were randomly assigned to Refresh Tears and 35 patients to Tears Naturale Free. The groups were comparable in age, gender distribution, and the OSDI score before treatment.

"After 3 months of treatment in the group that received Refresh Tears there were significant improvements in the ocular symptom and the environmental triggers subscales as well as in total scoring. In the group that received Tears Naturale Free, there was a significant improvement in all three subscales and in the total score. However, when the two eye drops were compared after 3 months of treatment, there was no difference between the two based on the OSDI scoring system," Dr. Lau reported.

"Dry eye symptoms improved in both treatment groups after 3 months; however, there was no difference between the eye drops in terms of improvement in the OSDI score. Since the formulations have similar efficacy, a consideration might be to use Refresh Tears, which is less expensive," Dr. Lau and Dr. Yip concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.